AlphAIAlphAI — Financial news for AI agents
benzinga.comSEP 91 min read$ILMN

This Illumina Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday - Illumina (NASDAQ:ILMN), Wate

Analysts upgraded five companies: Barclays raised Sagimet Biosciences (SGMT) to Overweight, targeting $18. B of A upgraded Figure Technology (FIGR) to Neutral, targeting $49. UBS upgraded Illumina (ILMN) to Buy, targeting $260. Wells Fargo upgraded Martin Marietta (MLM) to Overweight, targeting $609. UBS also upgraded Waters (WAT) to Buy, targeting $490.

Original reporting
benzinga.com
Published Sep 9, 2026, 4:40 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 9, 2026, 5:48 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$ILMN
Bullish
medium confidence
Mentioned
$ILMN · $SGMT · $FIGR · $MLM · $WAT
Relevance
5/10
AlphAI data visualization · based on benzinga.com
Decision brief

The 30-second read

$ILMNBullishMed
01

Why it matters

Upgrades collectively suggest a positive short‑term bias for the highlighted stocks.

02

Market read

The upgrades may trigger short‑term buying pressure across the listed names.

03

What to watch

Potential earnings volatility and macro headwinds not addressed.

Relevance 5/10Novelty 6/10Timing: today

Background

Analyst rating changes are compiled from multiple banks and reflect fresh target revisions.

Company-level read

Ticker impact

$ILMNBullishMedium confidence
Context

UBS upgraded Illumina to Buy and raised price target to $260.

Expected impact

Potential upside of 5-10% in short term.

Evidence & confidence

Upgrade from Neutral to Buy with a 23% higher target suggests strong upside.

$SGMTBullishMedium confidence
Context

Barclays upgraded Sagimet Biosciences to Overweight with target $18.

Expected impact

Possible 8-12% rally.

Evidence & confidence

Target more than double current price indicates significant upside.

$FIGRNeutralLow confidence
Context

B of A upgraded Figure Technology to Neutral with target $49.

Expected impact

Limited move, 2-4% range.

Evidence & confidence

Upgrade is modest; target modestly above current price.

$MLMBullishMedium confidence
Context

Wells Fargo upgraded Martin Marietta Materials to Overweight with target $609.

Expected impact

Potential 3-6% rise.

Evidence & confidence

Target modestly above price, indicating modest upside.

$WATBullishMedium confidence
Context

UBS upgraded Waters Corporation to Buy with target $490.

Expected impact

Possible 4-8% increase.

Evidence & confidence

Target ~22% above current price suggests upside.

Market effects

Sector

Analyst upgrades may lift biotech and materials sectors.

Regional

US equity markets could see modest gains in related sectors.

Global

Limited to US-listed stocks; no broad global effect.

Counterpoint

What could challenge this read

Upgrades may be premature if underlying fundamentals are weak.

Key entities

  • Analyst Firm
    UBS

    Provided upgrades for Illumina and Waters.

  • Analyst Firm
    Barclays

    Upgraded Sagimet Biosciences.

  • Analyst Firm
    B of A Securities

    Upgraded Figure Technology.

  • Analyst Firm
    Wells Fargo

    Upgraded Martin Marietta Materials.

Read at source← All news

Related articles

OCT 7
$FIGRMedAI 8/10

Figure Technology Solutions reports preliminary Q3 2026 marketplace volume of $5.12B; September volume $1.78B

Figure Technology Solutions reported preliminary Q3 2026 Consumer Loan Marketplace Volume of $5.12B, up 20% Q/Q, with September volume at $1.78B. The company noted Kiavi-originated volume will be included in formal Q3 results. Select product balances include $504M in $YLDS circulation and $588M in Democratized Prime matched offers as of September 30, 2026.

tradingview.com1 min
OCT 6
$FIGRMedAI 8/10

FIGURE TECHNOLOGY SOLUTIONS REPORTS PRELIMINARY September & Q3 2026 OPERATING DATA

Figure Technology Solutions, Inc. (FIGR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FIGURE TECHNOLOGY SOLUTIONS REPORTS PRELIMINARY September & Q3 2026 OPERATING DATA NEW YORK, October 6, 2026 (GLOBE NEWSWIRE) — Figure Technology Solutions, Inc. (Nasdaq: FIGR; OPEN: FGRS) (“Figure”), the leading blockchain-native capital marketplace for the originat

SEC EDGAR 8-K2 min
OCT 6
$FIGRMed

Figure reports Q3 consumer loan volume of $5.1 billion

Figure Technology reported Q3 2026 consumer loan volume of $5.1B, up 20% QoQ and 107% YoY, exceeding guidance. September volume was $1.8B, up 9% MoM. $YLDS in circulation rose 13% to $504M. Democratized Prime platform saw matched offers balance increase 50% QoQ to $588M. Results are preliminary and subject to change.

investing.com1 min
OCT 5
$ILMNMed

Illumina (ILMN) Shares Skyrocket, What You Need To Know

Illumina (ILMN) shares rose 7.7% after analysts raised price targets, citing expected clinical sales growth and AI applications. The stock closed at $293.84, up 7.6%. Illumina's shares have seen significant volatility, with a 22.4% gain last year on strong earnings. The company has raised its full-year EPS guidance to $4.70. ILMN is up 119% YTD, reaching a 52-week high.

financialcontent.com2 min
OCT 5
$FIGRMed

BofA cuts Figure Technology stock price target on lower loan volumes

BofA Securities lowered its price target for Figure Technology (FIGR) to $44 from $49, citing lower loan volumes and reduced earnings estimates. The new target implies a 54% upside from the current stock price of $28.53. The firm also cut its 2026, 2027, and 2028 earnings per share estimates. The stock trades at a P/E ratio of 43, and InvestingPro analysis suggests it is undervalued. BofA maintained a Neutral rating.

investing.com2 min